NCT01311466已完成不适用
Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)
Oslo University Hospital2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Over all survival
研究概览
简要总结
Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Uveal malignant melanoma
- •Liver metastases
排除标准
- •Extra hepatic disease
- •Previous other malignancy
- •Previous organ transplantation
结局指标
主要结局
Over all survival
时间窗: 1 year
Patient survival after livertransplantation
次要结局
未报告次要终点
研究者
Svein Dueland
MD PhD
Oslo University Hospital
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)Uveal MelanomaNCT04424719Institut Curie700
终止
不适用
Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal MelanomasMelanomaNCT02602756Centre Antoine Lacassagne32
终止
不适用
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver MetastasesMedium/Large Size Posterior Uveal MelanomaStage IIA Uveal MelanomaStage IIB Uveal MelanomaStage IIIA Uveal MelanomaStage IIIB Uveal MelanomaStage IIIC Uveal MelanomaIris MelanomaNCT02336763Jonsson Comprehensive Cancer Center2
招募中
1 期
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaUveal MelanomaMetastatic Uveal MelanomaMetastatic MelanomaMelanomaNCT05607095Memorial Sloan Kettering Cancer Center40
招募中
3 期
Duration of Anti-PD-1 Therapy in Metastatic MelanomaUnresectable/Metastatic MelanomaNCT02821013Canadian Cancer Trials Group614